Racing to Shorten Duration of Hep C Treatment
June 24, 2014
A 4-week hep C cure? Bristol to test drugs with Gilead’s Sovaldi
By Bill Berkrot
NEW YORK Fri Jun 20, 2014
(Reuters) – In the race to find a faster cure for hepatitis C, Bristol-Myers Squibb Co said it will test its experimental antiviral drug combination with Gilead Sciences Inc’s blockbuster drug Sovaldi, hoping to cut treatment time to four weeks.
Bristol-Myers disclosed plans for the exploratory 30-patient trial testing its three-drug combination with Sovaldi in an interview with Reuters. Eric Hughes, the leader of Bristol’s global hepatitis program, said the details were due to be posted on the clinicaltrials.gov website next week.
Continue reading this entire article:
Phase I Clinical Trial for Hepatitis C Drug Starts: ACH-3422
Which Big Name Protease Inhibitor Left the Hepatitis C Market?